Glucagon-like peptide-1 (GLP-1) agonists, such as liraglutide, are commonly used to manage type 2 diabetes mellitus (T2DM), and there is evidence suggesting that they also offer therapeutic benefits for various neurodegenerative diseases. This evidence concerns the gene GCG and diabetes mellitus.